Pirtobrutinib
- Generic Name
- Pirtobrutinib
- Brand Names
- Jaypirca
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21F4N5O3
- CAS Number
- 2101700-15-4
- Unique Ingredient Identifier
- JNA39I7ZVB
- Background
Pirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). Its high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation. Unlike BTK covalent inhibitors, such as ibrutinib, that bind to the cysteine 481 (Cys481) amino acid wi...
- Indication
Pirtobrutinib is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
- Associated Conditions
- Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma
- Associated Therapies
- -
A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT06215521
- Locations
- 🇺🇸
Covance Clinical Research Unit 1341 Mockingbird Lane, Dallas, Texas, United States
🇺🇸Covance Clinical Research Unit 3402 Kinsman Blvd, Madison, Wisconsin, United States
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06194214
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT06190691
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Pinnacle Clinical Research, San Antonio, Texas, United States
🇺🇸Orange County Research Institute, Anaheim, California, United States
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06190678
- Locations
- 🇺🇸
Riverside Clinical Research, Edgewater, Florida, United States
🇺🇸Orange County Research Institute, Anaheim, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 20
- Registration Number
- NCT06180980
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT06181006
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 15
- Registration Number
- NCT06180967
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06165146
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Loxo Oncology, Inc.
- Registration Number
- NCT06104683
- Locations
- 🇺🇸
Clinical Trial Network, Houston, Texas, United States
🇺🇸Swedish Medical Center-501 E Hampden Ave, Seattle, Washington, United States
🇵🇷Caribbean Center For Clinical Research Inc, Guaynabo, Puerto Rico
LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 12
- Registration Number
- NCT05990465
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.